Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 27, 2019 08:15 ET | Source: Kaleido Biosciences

Kaleido Biosciences Announces Upcoming Presentations at the Society for Inherited Metabolic Disorders Annual Meeting and The International Liver Congress™ (EASL)

Posters to feature ex vivo and in-human data supporting Kaleido’s Microbiome Metabolic Therapy programs for the treatment of hyperammonemia LEXINGTON, Mass., March 27, 2019 (GLOBE NEWSWIRE) --...
March 21, 2019 08:00 ET | Source: Kaleido Biosciences

Kaleido Biosciences Announces Initiation of Dosing in Non-IND Clinical Studies in Patients with Urea Cycle Disorders and Cirrhosis

Studies are evaluating novel Microbiome Metabolic Therapies, KB195 and KB174, in target patient populations; data expected in Q4 2019 Third non-IND clinical study in healthy subjects also underway to...
March 08, 2019 08:30 ET | Source: Kaleido Biosciences

Kaleido Biosciences to Highlight its Platform to Identify and Evaluate Microbiome Metabolic Therapies to Reduce Gut Ammonia Production in Presentation at Keystone Symposia on Microbiome

LEXINGTON, Mass., March 08, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the...
March 04, 2019 16:15 ET | Source: Kaleido Biosciences

Kaleido Biosciences Announces Closing of Initial Public Offering

LEXINGTON, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the...
February 27, 2019 19:27 ET | Source: Kaleido Biosciences

Kaleido Biosciences Announces Pricing of Initial Public Offering

LEXINGTON, Mass., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the...